Introductions and overview – Educational objectives of the programme - David Gerrett (UK)
Download PDF [1]
Setting the scene – the questions that need to be answered when selecting a biological - Wim Jiskoot (The Netherlands)
Download PDF [2]
Case study: what can go wrong? - Huub Schellekens (The Netherlands)
Download PDF [3]
Molecular biotechnology - Harald Sitte (Austria)
Download PDF [4]
Structure and analysis of recombinant proteins - Wim Jiskoot (The Netherlands)
Download PDF [5]
Production and downstream processing/purification - Wim Jiskoot (The Netherlands)
Download PDF [6]
Formulation - Bruno Gander (Switzerland)
Download PDF [7]
Route of administration, including biopharmaceutical considerations - Harald Sitte (Austria)
Download PDF [8]
PK/PD of peptide and protein drugs - Harald Sitte (Austria)
Download PDF [9]
Drug design - Harald Sitte (Austria)
Download PDF [10]
What have we learned? How will we teach it? What will we do tomorrow? - David Gerrett (UK)
Download PDF [11]
Welcome and recap on the day’s agenda - David Gerrett (UK)
Download PDF [12]
Safety of biological pharmaceuticals - Huub Schellekens (The Netherlands)
Download PDF [13]
Basic methodologies in biotechnology - Harald Sitte (Austria)
Download PDF [14]
Clinical trials - David Gerrett (UK)
Download PDF [15]
Biosimilars - Huub Schellekens (The Netherlands)
Download PDF [18]
Biopharmaceuticals and shifting paradigms - Daan Crommelin (The Netherlands)
Download PDF [19]
Pharmacoeconomics - David Gerrett (UK)
Download PDF [24]
Links
[1] https://www.eahp.eu/sites/default/files/files/01_01_Introduction_and_overview_Gerrett_(NXP).pdf
[2] https://www.eahp.eu/sites/default/files/files/01_02_Setting_the_scene_Jiskoot_(NXP).pdf
[3] https://www.eahp.eu/sites/default/files/files/01_03_Case_study_Schellekens_(NXP).pdf
[4] https://www.eahp.eu/sites/default/files/files/01_04_Molecular_biotechnology_Sitte_(NXP).pdf
[5] https://www.eahp.eu/sites/default/files/files/01_05_Structure_%26_analysis_of_recombinant_proteins_Jiskoot.pdf
[6] https://www.eahp.eu/sites/default/files/files/01_06_Production_%26_downstream_processing_Jiskoot.pdf
[7] https://www.eahp.eu/sites/default/files/files/01_07_Formulation_Gander_(NXP).pdf
[8] https://www.eahp.eu/sites/default/files/files/01_08_Route_of_administration_Sitte_(NXP).pdf
[9] https://www.eahp.eu/sites/default/files/files/01_09_PK-PD_of_peptide_%26_protein_drugs_Sitte.pdf
[10] https://www.eahp.eu/sites/default/files/files/01_10_Drug_design_Sitte_(NXP).pdf
[11] https://www.eahp.eu/sites/default/files/files/01_11_What_have_we_learned_day1_Gerrett_(NXP).pdf
[12] https://www.eahp.eu/sites/default/files/files/02_01_Recap_on_the_days_agenda_Gerrett_(NXP).ppt
[13] https://www.eahp.eu/sites/default/files/files/02_02_Safety_of_biological_pharmaceuticals_Schellekens_(NXP).pdf
[14] https://www.eahp.eu/sites/default/files/files/02_03_Basic_methodologies_in_biotechnology_Sitte_(NXP).pdf
[15] https://www.eahp.eu/sites/default/files/files/02_04_Clinical_trials_Gerrett_(NXP).pdf
[16] https://www.eahp.eu/sites/default/files/files/02_05a_Handling_in_the_pharmacy_Tredree_(NXP).pdf
[17] https://www.eahp.eu/sites/default/files/files/02_05b_Handling_in_the_pharmacy_M%C3%B6ll_(NXP).pdf
[18] https://www.eahp.eu/sites/default/files/files/02_06_Biosimilars_Schellekens_(NXP).pdf
[19] https://www.eahp.eu/sites/default/files/files/02_07_Biopharmaceuticals_%26_shifting_paradigms_Crommelin_(NXP).pdf
[20] https://www.eahp.eu/sites/default/files/files/02_08_Clinical_governance_Gerrett_(NXP).pdf
[21] https://www.eahp.eu/sites/default/files/files/03_01_Recap_on_the_days_agenda_day3_Gerrett_(NXP).pdf
[22] https://www.eahp.eu/sites/default/files/files/03_02a_Biopharmaceuticals_for_immunological_intervention_Jiskoot_(NXP).pdf
[23] https://www.eahp.eu/sites/default/files/files/03_02b_Biopharmaceuticals_for_immunological_intervention_Schellekens_(NXP).pdf
[24] https://www.eahp.eu/sites/default/files/files/03_03_Pharmacoeconomics_Gerrett_(NXP).pdf